Journal: Cancers

Article Title: Paquinimod Targeting of the S100A8/A9 Axis Suppresses Liver Metastasis in Aged Mice

doi: 10.3390/cancers18101635

Figure Lengend Snippet: Association of S100A9 inhibition with lower tumor burden and altered immune cell composition in aged metastatic livers. ( A ) Experimental schema of tumor cell inoculation and every other day paquinimod or vehicle administration in young and aged mice. ( B ) Representative IVIS bioluminescence images of liver metastases at days 14 and 21 after tumor inoculation (left). Comparisons of tumor burden (radiance) between day 14 and day 21 within each treatment group are shown (upper right); paired t -tests were performed (Young: n = 3 per group; Aged: n = 7 per group). The change in tumor burden (Δlog10 photons/sec/cm 2 /sr) from day 14 to day 21 is summarized (lower right) for young and aged mice. For the Δlog10 bar graphs, vehicle- and paquinimod-treated mice were compared using unpaired Student’s t -tests (n = 3 young and n = 7 aged). ( C ) Representative macroscopic appearance of livers (left) and quantification of the number of metastatic nodules and the tumor area ratio (right) at day 21 (n = 7 per group). ( D – F ) Representative flow cytometry plots and frequencies of tumor-infiltrating immune cells at day 21 after tumor inoculation, including Ly6G + cells, Ly6C + monocytes, PMN-MDSCs (Ly6G + CD244 + ), CD4 + and CD8 + T cells, and NK cells. Absolute numbers are shown alongside frequencies (n = 3 per group). ( G ) Correlation between day 21 tumor burden and frequencies of the indicated immune cell populations in aged mice, assessed by simple linear regression; R 2 and p values are shown. (n = 14 aged mice). Data are presented as mean ± SEM. Statistical analyses were performed using Student’s t -test, paired t -test, or the Mann–Whitney U test, as appropriate. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: S100A9 inhibition studies were performed using the small-molecule inhibitor Paquinimod (HY-100442; MedChemExpress, Monmouth Junction, NJ, USA), also known as ABR215757 [ , ].

Techniques: Inhibition, Flow Cytometry, MANN-WHITNEY

Journal: bioRxiv

Article Title: Sortilin deficiency alters baseline retinal homeostasis and injury-induced signaling without affecting optic nerve crush-induced neurodegeneration

doi: 10.64898/2026.05.08.723723

Figure Lengend Snippet: A. Experimental plan: Following baseline optical coherence tomography (OCT) scans, C57BL6/JRj mice were subjected to optic nerve crush (ONC) in one eye and sham procedure in the other eye. Immediately after, mice were randomized to receive intravitreal (IVT) injection of either the anti-sortilin polyclonal antibody (pAb) AF2934 or IgG control (2 µL of 1 µg/µL) in the crush eye while the other served as untreated sham control. Mice were sacrificed following OCT at 14 days post crush (dpc). B. Bar plot (mean ± sd) showing quantification of the change from baseline of the combined thickness of the nerve fiber, ganglion cell and inner nuclear layer, denoted the NGI thickness. Statistical comparisons were performed using one-way ANOVA followed by Tukey’s test (n > 5). C. Bar plot (mean ± sd) showing quantification of the density of RNA-binding protein with multiple splicing (RbPMS) positive retinal ganglion cells (RGCs) in retinal flat mounts. Statistical comparisons were performed by one-way ANOVA followed by Tukey’s test (n > 5). Representative OCT scans (D) and areas from anti-RbPMS (red) immunostained retinal flat mounts (E) are shown. Scale bars 50 µm. F. Experimental plan: As in (A), C57BL6/JRj mice were randomized to receive IVT injection of the small-molecule inhibitor AF38469 (2 µL of 1 µg/µL) or vehicle (PBS-1% DMSO) in the crush eye. G. Bar plot (mean ± sd) showing quantification of the change from baseline of NGI thickness. Statistical comparisons were performed by one-way ANOVA followed by Tukey’s test (n > 5). H. Bar plot (mean ± sd) showing quantification of RGC density in retinal flat mounts. Statistical comparisons were performed by one-way ANOVA followed by Tukey’s test (n > 5). Representative OCT scans (I) and areas from anti-RbPMS (red) immunostained retinal flat mounts (J) are shown. Scale bars 50 µm. Significance levels: * [0.01, 0.05]; ** [0.001,0.01]; *** [0.0001, 0.001]; **** [0, 0.0001].

Article Snippet: In the second experiment, the small-molecule inhibitor AF38469 (MedChemExpress LLC, Monmouth Junction, NJ, USA) was compared with the buffer solution.

Techniques: Tomography, Injection, Control, RNA Binding Assay

Journal: Current Oncology

Article Title: Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications

doi: 10.3390/curroncol33050280

Figure Lengend Snippet: Compartment-specific functions of Galectin-3 and therapeutic targeting strategies in prostate cancer.

Article Snippet: Melanoma & HNSCC , Immune Escape: Gal-3 acts as a negative immune checkpoint, blocking anti-PD-1 antibody binding to T-cells. , Belapectin + Pembrolizumab , Small molecule Galectin-3 inhibitor , Phase I study showed objective response rates of 50% (melanoma) and 33% (HNSCC). Demonstrates that Gal-3 inhibitors may enhance immunotherapy by reversing immune suppression [ , ]. .

Techniques:

Journal: Current Oncology

Article Title: Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications

doi: 10.3390/curroncol33050280

Figure Lengend Snippet: Compartment-specific functions of Galectin-3 and therapeutic targeting strategies in prostate cancer.

Article Snippet: Lung & Pancreatic Cancer , KRAS Addiction: Gal-3 supports pro-survival pathways in KRAS-driven tumors. , GB1107 , Novel small molecule Galectin-3 inhibitor , Identified as a druggable vulnerability in hard-to-treat tumors, showing Gal-3 as a key mediator of oncogenic signaling beyond the AR pathway [ ]. .

Techniques: